A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD

…, L de Teresa, W De Backer, MT Zvarich… - European …, 2014 - Eur Respiratory Soc
Fluticasone furoate/vilanterol trifenatate (FF/VI) is a once-daily inhaled corticosteroid/long-acting
β 2 -agonist combination in development for chronic obstructive pulmonary disease (…

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way …

JA Boscia, KK Pudi, MT Zvarich, L Sanford… - Clinical …, 2012 - Elsevier
BACKGROUND: Available inhaled corticosteroid/long-acting β 2 -agonist combinations for
chronic obstructive pulmonary disease (COPD) require twice-daily administration. The …

Effect Of Fluticasone Furoate (FF)/Vilanterol (VI) Administered Once Daily On 24h Pulmonary Function In Patients With COPD: A Randomized, Three-Way, Incomplete …

JA Boscia, KK Pudi, MT Zvarich, L Sanford… - B41. COPD …, 2012 - atsjournals.org
Effect Of Fluticasone Furoate (ff)/vilanterol (vi) Administered Once Daily On 24h Pulmonary
Function In Patients With COPD: A Ra Page 1 / Thematic Poster Session / Monday, May 21/8:15 …

Innoviva (INVA) 8-K Other Events

JA Boscia, KK Pudi, MT Zvarich, L Sanford, C Crim - COPD - capedge.com
OBJECTIVES· To evaluate the 24-h spirometric effect of FF/VI compared with placebo in
patients with COPD. METHODS

Innoviva, Inc.-FORM 8-K-EX-99.3-May 21, 2012 Attached files

JA Boscia, KK Pudi, MT Zvarich, L Sanford, C Crim - COPD - getfilings.com
OBJECTIVES· To evaluate the 24-h spirometric effect of FF/VI compared with placebo in
patients with COPD. METHODS

Concordance of Death Certificates with Adjudicated Cause of Death: Analysis from the TORCH Study.

…, M John, LP McGarvey, MT Zvarich… - C47. COPD …, 2009 - atsjournals.org
Methods: Using evaluable certificates, 3 reviewers assessed concordance between listed
and adjudicated causes of death and whether COPD was listed on the DC. Results: Of 398 …

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

LP McGarvey, M John, JA Anderson, M Zvarich… - Thorax, 2007 - thorax.bmj.com
Background: TORCH (Towards a Revolution in COPD Health) is an international multicentre,
randomised, placebo-controlled clinical trial of inhaled fluticasone propionate/salmeterol …

[HTML][HTML] Recurrent horizontal transfer identifies mitochondrial positive selection in a transmissible cancer

…, SAE Widdowson, I Zvarich… - Nature …, 2020 - nature.com
Autonomous replication and segregation of mitochondrial DNA (mtDNA) creates the potential
for evolutionary conflict driven by emergence of haplotypes under positive selection for ‘…

Linear autoregressive processes with periodic structures as models of information signals

VN Zvarich, BG Marchenko - Radioelectronics and Communications …, 2011 - Springer
… VN Zvarich and BG Marchenko … VN Zvarich and BG Marchenko, “The Method of Determining
Characteristic Functions of the Generating Processes for Linear Autoregression Processes,” …

[CITATION][C] Reliability of cause-specific mortality adjudication in a COPD clinical trial

…, LP McGarvey, M John, JA Anderson, MT Zvarich - Proc Am Thorac Soc, 2006